3 brands lead the HIV treatment market. How does your brand stack up?
Satisfaction is running high for HIV treatments in the US Market. But Infectious Disease specialists show a clear preference for fixed-dose combinations. Find out how single-pill monotherapies compare, which 3 brands are fighting for first place, and how your brand measures up.
FirstView's NPS+ HIV report compares brand loyalty for 8 major HIV treatments-information you can use to improve your brand's health, and boost your market share.
Based on your net promoter score (NPS), the report shows you how likely doctors are to recommend your brand-and your competitors. A detailed breakdown of brand associations helps you see which marketing messages are likely to succeed, while a unique "Brand DNA" section reveals doctors' candid thoughts about your brand.
Intuitive, easy-to-use KPIs highlight areas for improvement and make your next steps crystal clear.
Full Report Details at
- http://www.fastmr.com/prod/1152010_nps+_hiv_us.aspx?afid=301
Not your market? Click here to see the EU5 Edition.
Get Answers to Key Questions about HIV Treatments
* Evotaz (Atazanavir/Cobicistat; Bristol-Myers Squibb/Gilead): Is lack of experience with Evotaz stopping doctors from recommending it?
* Intelence (Entravirine; Janssen Pharma): Intelence and Evotaz have similar NPS scores. Which has more promoters?
* Isentress (Raltegravir; Merck & Co.): What other drug do some surveyed doctors prefer to Isentress?
* Selzentry (Maraviroc; ViiV Healthcare): Is the need for complicated lab tests preventing doctors from recommending Selzentry?
* Stribild (Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Gilead): Which brand stands to gain more market share by winning over detractors, Stribild or Triumeq?
* Triumeq (Abacavir/dolutegravir/lamivudine; ViiV Healthcare): Promoters highlight Triumeq's ease of use, but is it a big driver of recommendations?
* Truvada (Emtricitabine/tenofovir disoproxil fumarate; Gilead): Truvada, Triumeq and Stribild have nearly the same number of Promoters. Which has the higher NPS?
* Viread (Tenofovir disoproxil fumarate; Gilead): In Europe, Viread has a low NPS and a lot of Detractors. Is it doing better in the US market?
Top Takeaways
* More than half of the surveyed brands have a positive NPS: But the top three score 4-5 times higher than the nearest competitor.
* Market leader doesn't get top score: Although one mainstay brand has an overwhelming lead in market share, a newer brand earns a slightly higher NPS.
* Fixed-dose combinations score higher: NPS scores are considerably higher than for monotherapies, and only one monotherapy makes the top 4.
* One leading brand poised for a massive share gain: Up to nearly 5 times more than any other surveyed brand if it can turn its Detractors into Promoters.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)
You may also be interested in these related reports:
- NPS+ HIV (EU5)
- PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2023
- EpiCast Report: Human Immunodeficiency Virus (HIV) - Epidemiology Forecast to 2023
- HIV-Associated Lipodystrophy Syndrome Global Clinical Trials Review, H2, 2015
- Global HIV Drugs Market 2015-2019
Now Available: NPS+ HIV (US)
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001